Treatment with SGLT2 inhibitors was associated with a 27% relative risk reduction of HHF or CV mortality (RR = 0.73, 95% CI = 0.68–0.78).
Why the study?
SGLT2 inhibitors are increasingly relevant for heart failure, prompting an investigation into various SGLT2 inhibitors in patients with established HF, with a focus on different HF types.
Do SGLT2 inhibitors reduce the composite of hospitalization for heart failure or cardiovascular mortality in patients with established heart failure?
Population
20,749 participants across 17 RCTs with established HF at baseline
Comparison
SGLT2 inhibitors vs comparator
Design
Meta-analysis of randomized controlled trials
Authors
Discussion
Loading...
Member takes
Overview
SGLT2 inhibitors should be initiated in patients with established HF; reinforces consistent benefits across phenotypes and agents in Level 1 evidence.
Structured PICO
Do SGLT2 inhibitors reduce the composite of hospitalization for heart failure or cardiovascular mortality in patients with established heart failure?
P
Population
17 RCTs pooling 20,749 patients with established heart failure at baseline.
I
Intervention
SGLT2 inhibitors as a class
C
Comparator
Comparator (not further specified in abstract)
O
Outcome
Composite of hospitalization for HF (HHF) or cardiovascular (CV) mortalitycomposite
SGLT2 inhibitors significantly reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with established heart failure, independent of diabetes status or heart failure type.
Cite This Study
Gager et al. (2021) studied this question.